Biotech Top 50 Innovators — ReviR Therapeutics, Jingzhi Future, and Yuanguji Submit IPO Filings

"Weekly Corporate News"

Top 50 Biotech Rising Star - ReviR Therapeutics, Inc. Completes New Round of Strategic Investment, the investor is CMT Research Foundation CMTRF, a non-profit organization. Both parties will promote the research of small molecule targeted RNA therapies that modulate the expression of the CMT1A pathogenic gene in their cooperation.

ReviR Therapeutics, founded in May 2021, is located in Nanshan District, Shenzhen, with its parent company based in Hong Kong. It is an AI-driven targeted RNA drug developer and an innovative drug research company powered by artificial intelligence algorithms and gene technology. Focusing on RNA spatial structure computation, the company has built the voyageR™ AI platform to develop small-molecule drugs targeting RNA. ReviR Therapeutics is committed to advancing AI algorithm- and gene technology-driven drug discovery for targeted RNA to address long-unmet clinical needs in oncology, infectious diseases, and rare diseases.

Top 50 Emerging Biotech Companies of the Sixth Session ——ChromX HealthCompany Reaches Cooperation Consensus with Guangzhou Medical University First Affiliated Hospital, officially launching in-depth research on the differentiation and diagnosis of multiple lung diseases through VOCs, aiming to construct a comprehensive disease spectrum map of exhaled VOCs and promote the application of exhaled VOC detection technology in the field of medical diagnosis.

ChromX Health has innovatively integrated MEMS (Micro-Electro-Mechanical Systems), Microfluidic, and AI (Artificial Intelligence) technologies based on the theoretical foundation of breath metabolomics. The company has independently developed and manufactured the world’s first “MEMS + AI Micro GC” one-stop breath analysis platform. This platform combines an ultra-sensitive, high-resolution, intelligent Point-of-Care Testing (POCT) micro gas chromatograph for breath molecule analysis with ChromX Health's global XCloud breath metabolomics cloud platform. It enables precise qualitative and quantitative analysis of volatile organic compounds (VOCs) in human breath, making real-time, on-site disease diagnosis through breath analysis a reality. This provides a non-invasive, rapid, convenient, and affordable full-stack, integrated application model for early cancer screening, fast disease diagnosis, and home monitoring of chronic diseases.

Recently,Top 50 Biotech Emerging Company — GuangANCIENT TIMES OF GENOMICS Completes Series B Equity FinancingThis round of financing was led by the fund under Baiyun Financial Holdings, with Junshan Asset Management and Mingzhe Asset following up. The total investment amount reached tens of millions of yuan, jointly supporting ANCIENT TIMES OF GENOMICS to further develop at a high speed.

ANCIENT TIMES OF GENOMICS was founded in 2019 as a comprehensive solutions provider specializing in precise clinical diagnosis and treatment within the respiratory specialty. ANCIENT TIMES OF GENOMICS has received multiple honorary certifications, including "Specialized, Fine, and Innovative Small and Medium Enterprise," "High-tech Enterprise," "Innovative Small and Medium Enterprise," and "Science and Technology-Oriented Small and Medium Enterprise."